# QIBA fMRI Biomarker Committee (BC) Call

Thursday, June 1, 2017 at 11 AM CT Call Summary

| In attendance                |                       |                     | RSNA           |
|------------------------------|-----------------------|---------------------|----------------|
| Jay J. Pillai, MD (Co-Chair) | Feroze Mohamed , PhD  | David Soltysik, PhD | Joe Koudelik   |
| James Reuss, PhD (Co-Chair)  | Nancy Obuchowski, PhD | James Voyvodic, PhD | Susan Weinmann |
| Andrew Kalnin, MD            |                       |                     |                |

#### **Announcements**

- Dr. Petrella has stepped down as BC Co-chair and was thanked for his valuable service
- Dr. Pillai was welcomed as he took on the role of fMRI BC Co-chair

# **Review of Previous Call Summary**

• The 5.3.2017 call summary was approved as presented

## fMRI Profile v1.0 draft (All)

- Vote-to-release e-ballot, sent out to seventeen MR CC eligible voters, closed with 10 "Yes" and 0 "No," thus
  approving Profile release
- The fMRI Profile v1.0 draft will move to the Public Comment Stage as described on the QIBA Wiki at: <a href="http://qibawiki.rsna.org/index.php/Public Comment Process">http://qibawiki.rsna.org/index.php/Public Comment Process</a>
  - The Profile draft-for-release will be sent to RSNA staff to be posted on the Profiles page of the QIBA
     Wiki at: http://qibawiki.rsna.org/index.php/Profiles
  - An announcement including a link to the Public Comment form will then be sent to the 1,000+ QIBA membership roster and approximately 100 sister association contacts
  - o fMRI BC Chairs to send names, email addresses and specialized language for a separate announcement to subject matter experts, e.g., ASFNR contacts expected
  - o The announcement notes that recipients may forward it to anyone else who may be interested
  - Public comment stage is typically 2 3 months long
- Public comments to be collated and addressed after the close of this stage, but fMRI BC leadership may request status updates throughout the public comment period

#### **DRO Specifications and Creation of 1.0 Assessment Sets**

- Additional sites to create variety of DROs may be needed
- Discussion on DROs to be generated and how to use them to test conformance
  - o Performance specifications in Profile to be resolved to help determine what kind of DROs are needed
  - Those who plan to create DROs can share work and tools
  - Range of data quality needed (good to bad) based upon a variety of DROs that range in measurement difficulty

### **DICOM Supplement 189 - Final Text (Dr. Reuss)**

- The final text can be found here: ftp://medical.nema.org/medical/dicom/final/sup189 ft.pdf
- Current progress on new DICOM supplements can be found here:
   <a href="http://dicom.nema.org/Dicom/News/Current/index.html">http://dicom.nema.org/Dicom/News/Current/index.html</a>
- Supplement 189 blends functional imaging
- Multiple imaging volumes are blended
- Based upon parametric map technology
- In effort to demonstrate greater DICOM value, a Connectation status was suggested to gain traction with manufacturers, e.g., manufacturers to demonstrate DICOM 'tractography'

# **Profile 2.0 Language Mapping (Dr. Reuss)**

- Volunteers needed for literature search for fMRI Profile v2.0
- Dr. Mohamed to work with his students on language applications and verifications
- Focus of articles to choose for review should be on quantitative language mapping and reproducibility
- Drs. Pillai and Voyvodic are drafting manuscripts related to their Round-5 groundwork project; Dr. Pillai's project dealt mostly with reproducibility of language localization and lateralization.
- ASFNR white paper recommendations are based on the mostly clinically viable and widely accepted language paradigms
- Discussion as to whether more quantitative assessment of paradigms is needed since the white paper only makes qualitative statements.
- Dr. Pillai selected only the two most highly recommended language-mapping paradigms for his Round-5 project based on ASFNR recommendations, i.e., the paradigms that were used in the ASFNR multicenter trial and recommended in the ASFNR white paper; these are also described on the following website:https://www.asfnr.org/paradigms/

### Next calls:

- QIBA fMRI Bias TF call TBD
- QIBA fMRI Biomarker Committee call Wednesday, June 14 at 11am CT